key: cord-0947892-cci5ozeu
authors: Mahendran, A.J.; Gupta, Nitesh; Ish, Pranav
title: HCQ induced QT prolongation- Primum non nocere
date: 2020-07-01
journal: Indian Pacing Electrophysiol J
DOI: 10.1016/j.ipej.2020.06.009
sha: 976f4019e4f5193982b3f7651f8a5de31b7e760e
doc_id: 947892
cord_uid: cci5ozeu

nan

Based on the existing evidences, though not conclusive, HCQ has been recommended for use as prophylaxis and treatment in many guidelines.

Although it is a safe drug, a serious adverse effect is QT prolongation, culminating in Torsades des Pointes or polymorphic ventricular tachycardia, leading to sudden cardiac death. Unfortunately, only few published literatures speak about the adverse reaction and precautions to be taken before using the drug (Table 1) .

It is well known fact that QT c is calculated using various formulae viz., Bazett, Fridericia, Framingham, Hodges and Rautaharju. For drug induced QT c prolongation, the study by Vanderberk et al advocated to use Fridericia or Framingham formula instead of Bazett formula, which may under correct QT c prolongation at low heart rate and overcorrect at high heart rate. [2] However, the Indian heart rhythm society [1] has recommended use of Bazett formula. In view of lack of studies comparing various formulae on a head-to-head basis and ease of using online calculators, the reason for choosing the particular formula is unclear. There is an urgent need to carry out further studies to look into the occurrence of Torsades de pointes and QTc prolongation with HCQ using various formulae and develop international guidelines for the same. 

Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society

Which QT Correction Formulae to Use for QT Monitoring? J Am Heart Assoc Cardiovasc Cerebrovasc Dis

Accessed on

Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 -American College of Cardiology

Fact sheet for health care providers emergency use authorization (eua) of hydroxychloroquine sulfate supplied from the strategic national stockpile for treatment of covid-19 in certain hospitalized patients. Last accessed on

Indian pacing and electrophysiology journal [1] April, 2020

 [3] April 7, 2020 No recommendation 9 WHO-Landscape analysis of therapeutics [3] March 21, 2020 No recommendation CDC-Centre for disease control, FDA-Food and Drug Administration, ICMR-Indian council of medical research, BMJ-British medical journal, WHO-World health organisation

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: